Mark Chiang

Mark Chiang

Managing Director

LinkedIn Profile

Mr. Chiang brings more than 17 years of experience to Signal Hill, including over 60 completed M&A transactions and numerous equity and debt financings. He is a member of the firm’s Healthcare Services group with subsector focus on Hospitals & Health Systems, Healthcare Distribution & Pharmacy, Physician Groups, and Managed Care, Care Management, Accountable Care Organizations, and Population Health.

Mr. Chiang has successfully advised corporate executives, founders/families, financial sponsors, investors and boards of directors, providing independent capital markets and financial advice. Also, he has a strong track record advising clients who have not historically accessed institutional funding. At Signal Hill, Mr. Chiang continues to expand his mergers & acquisitions and financial advisory practice with sell-side and buy-side M&A and growth capital placements.

Mr. Chiang has additional healthcare sector transaction experience advising clients in the Ambulatory Surgery, Behavioral / Psychiatric Care, Cancer Treatment, Contract Research and Manufacturing Organizations, Dental Care and Supply, GPOs, HCIT, Home Health, Laboratories, Medical Imaging, PBM, Rehabilitation, REITs, Revenue Cycle Management, Skilled Nursing and Senior Living Facilities, Staffing, Tele-medicine, Vision, Medical Devices, Biopharmaceutical and Life Sciences sectors.

Before joining Signal Hill, he served as Deputy Head of Hospitals & Health Systems M&A investment banking at Jefferies LLC.  Previously, he served as a Director in the Global Mergers & Acquisitions Group of the investment banking division of Citigroup Global Markets, Inc. / Salomon Smith Barney, originating and executing Healthcare M&A. Other investment banking experience includes serving as a Senior Vice President in the Healthcare Investment Banking group of Ernst & Young Capital Advisors, LLC.

Mr. Chiang has advised clients with respect to corporate mergers, divestitures, acquisitions, joint ventures, equity and debt private and public capital raises, LBO and recapitalizations, contested M&A and defense, MOEs, going-private 13e-3s squeeze-outs, tracking stock, contingent consideration, M&A collars and forward purchase options, spinoffs and Reverse Morris Trusts, cross-border M&A, IRC §338(g) and 338(h)10 elections, and §382 NOL utilization. He has significant experience with public company mergers and tender offers.

Mr. Chiang is a graduate of the University of Pennsylvania, having earned a B.S. in Economics (finance concentration) from The Wharton School of Business and a B.A. in Biochemistry from The College of Arts and Sciences.

Notable clients Mr. Chiang has advised in publicly announced M&A transactions include: Bindley Western Industries, Inc. (NYSE: BDY); Broadlane, a subsidiary of Tenet Healthcare Corporation (NYSE: THC); Cardinal Health, Inc. (NYSE: CAH); China Airlines (TWSE: 2610); Conor MedSystems, Inc. (Nasdaq: CONR); Cariten Health Plan, a subsidiary of Covenant Health (TN); D&K Healthcare Resources, Inc. (Nasdaq: DKHR); E. I. du Pont de Nemours & Company (NYSE: DD); Emdeon Corporation (Nasdaq: HLTH); excelleRx, Inc., a portfolio company of LLR Partners; Express Scripts, Inc. (Nasdaq: ESRX); General Medical, Inc., a portfolio company of Kelso & Co.; Gentle Dental Services Corp. (Nasdaq: GNTL) and Dental Care Alliance, Inc. (Nasdaq: DCAI) now known as InterDent, Inc.; GMI Gesellschaft fur Angewandte Mathematik und Informatik mbH; Heller Financial, Inc. (NYSE: HF) & GATX Corporation (NYSE: GMT); Highmark BCBS; Hudson RCI, a portfolio company of Freeman Spogli; Inveresk Research, a portfolio company of SGS Group; LifePoint Hospitals, Inc. (Nasdaq: LPNT); Medical Services Company, a portfolio company of H.I.G. Capital; Memorial Health Services (CA); Montefiore Health System (NY); Owens & Minor, Inc. (NYSE: OMI); Psychiatric Solutions, Inc. (Nasdaq: PSYS); Psychiatric Solutions, Inc. (Nasdaq: PSYS); Sunrise Senior Living, Inc. (NYSE: SRZ); Syncor International Corporation (Nasdaq: SCOR); Tandem Health Care, Inc., a portfolio company of Behrman Capital; Tenet Healthcare Corporation (NYSE: THC); The Carlyle Group; the independent committee of the board of directors of Phoenix Investment Partners Ltd. (NYSE: PXP); University of Miami Health System (FL); and Valley Wholesale Drug Company, Inc.

Notable clients Mr. Chiang has advised in publicly announced financing transactions include: BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX); Coast Dental Services, Inc. (Nasdaq: CDEN); McKesson Corporation (NYSE: MCK); Parexel International (Nasdaq: PRXL); Pediatric Services of America, Inc. (Nasdaq: PSAI); Quintiles Transnational Corporation (Nasdaq: QTRN); Romac International (Nasdaq: ROMC); Thermo BioAnalysis, Inc. (Amex: TBA); Thermo Electron Corporation (NYSE: TMO); and Triad Hospitals, Inc. (NYSE: TRI).